Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.44 |
| ▸ | ABL1 | P00519 | 5/20 | 0.44 |
| ▸ | EGFR | P00533 | 5/20 | 0.44 |
| ▸ | HCK | P08631 | 5/20 | 0.44 |
| ▸ | SRC | P12931 | 5/20 | 0.44 |
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.44 |
| ▸ | MTOR | P42345 | 5/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 5/20 | 0.44 |
| ▸ | PRKDC | P78527 | 5/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593698 | 0.92 | TNK2 (0.47) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL595253 | 0.76 | TNK2 (0.60) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL593553 | 0.75 | RET (0.53) | PIK3CAPIK3CDABL1EGFRSRC | |
| SCHEMBL399401 | 0.74 | IGF1R (0.63) | EGFRKDRIGF1R | |
| SCHEMBL4360053 | 0.74 | TNK2 (0.61) | TNK2IGF1R | |
| SCHEMBL1128695 | 0.74 | TNK2 (0.60) | TNK2 | |
| SCHEMBL13504882 | 0.72 | TNK2 (0.65) | TNK2 | |
| SCHEMBL402180 | 0.72 | IGF1R (0.51) | EGFRKDRTNK2IGF1R | |
| SCHEMBL401943 | 0.71 | IGF1R (0.46) | TNK2IGF1R | |
| SCHEMBL399076 | 0.71 | IGF1R (0.50) | TNK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2325186-B1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS LLC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8796455-B2 | Fused bicyclic mTOR inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8586546-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2385053-B1 | Intermediates for the preparation of fused bicyclic mTOR inhibitors | OSI PHARM INC (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI Pharmaceuticals, LLC | 2013-06-27 | — | — | US | disclosed |
| US-8314111-B2 | Fused bicyclic motor inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | OSI PHARMACEUTICALS, LLC. | 2012-08-16 | — | — | US | disclosed |
| US-8114846-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2385053-A2 | Intermediates for the preparation of fused bicyclic mTOR inhibitors | OSI Pharmaceuticals, Inc. (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110218183-A1 | Fused Bicyclic mTOR Inhibitors | OSI Pharmaceuticals, LLC | 2011-09-08 | — | — | US | disclosed |
| EP-1951724-B1 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARM INC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-7923555-B2 | Fused bicyclic mTor inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100099679-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARMACEUTICALS, INC. | 2010-04-22 | — | — | US | disclosed |
| US-7700594-B2 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7651687-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | PIK3CA 25/4885PIK3CD 57/4885ABL1 430/4885 |
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | EGFR, ERBB2, MTOR | PIK3CA 14/4885PIK3CD 71/4885ABL1 22/4885 |
| US-20100099679-A1 | FUSED BICYCLIC mTOR INHIBITORS | MTOR, RICTOR, MAPKAP1 | PIK3CA 25/4885PIK3CD 57/4885ABL1 430/4885 |
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | MTOR, RICTOR, MAPKAP1 | PIK3CA 25/4885PIK3CD 57/4885ABL1 430/4885 |
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | PIK3CA 10/4885PIK3CD 17/4885ABL1 675/4885 |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | EGFR, ERBB2, RICTOR | PIK3CA 57/4885PIK3CD 272/4885ABL1 132/4885 |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | EGFR, ERBB2, RICTOR | PIK3CA 57/4885PIK3CD 272/4885ABL1 132/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | PIK3CA 90/4885PIK3CD 121/4885ABL1 1104/4885 |
| US-20110218183-A1 | Fused Bicyclic mTOR Inhibitors | MTOR, RICTOR, MAPKAP1 | PIK3CA 25/4885PIK3CD 57/4885ABL1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.